Vertex Pharmaceuticals Incorporated (LON:0QZU)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 80.80B |
| Revenue (ttm) | 8.33B |
| Net Income (ttm) | 2.66B |
| Shares Out | n/a |
| EPS (ttm) | 10.27 |
| PE Ratio | 30.43 |
| Forward PE | 21.40 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 334 |
| Average Volume | 444 |
| Open | 420.00 |
| Previous Close | 419.98 |
| Day's Range | 416.21 - 423.00 |
| 52-Week Range | 362.50 - 519.68 |
| Beta | 0.43 |
| RSI | 54.64 |
| Earnings Date | Nov 3, 2025 |
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The com... [Read more]
News
JEPQ, ADI, VRTX, ORLY: Large Outflows Detected at ETF
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the JPMorgan Nasdaq Equity Premium Income ETF (Symbol: JEPQ) where we have...
Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK® at the North American Cystic Fibrosis Conference
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the presentation of multiple abstracts demonstrating the clinical benefits of treatment with CFTR modulators...
Insiders Bullish on Certain Holdings of JDOC
A look at the weighted underlying holdings of the JPMorgan Healthcare Leaders ETF (JDOC) shows an impressive 11.8% of holdings on a weighted basis have experienced insider buying within the past six m...
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.
ClearBridge Select Strategy buys REGN, VRTX & VST; exits ICLR, PCTY & ADBE
Discover how ClearBridge Select Strategy outperformed major indices in Q3 2025 and see the key stock moves driving future portfolio growth.
Vertex Pharmaceuticals (VRTX) Advances Povetacicept for Kidney Disease Treatment
Vertex Pharmaceuticals (VRTX) Advances Povetacicept for Kidney Disease Treatment
Vertex Pharmaceuticals (VRTX) Advances Development of Key Therapeutic
Vertex Pharmaceuticals (VRTX) Advances Development of Key Therapeutic
Vertex IgA nephropathy asset povetacicept granted FDA rolling review
Vertex Pharmaceuticals receives FDA rolling review for its IgA nephropathy drug candidate povetacicept. Read more here.
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal developme...
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombi...
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know
In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $407.9, denoting a -1.05% move from the preceding trading day.
Vertex Pharmaceuticals (VRTX): Analyst Rating Update from Morgan Stanley | VRTX Stock News
Vertex Pharmaceuticals (VRTX): Analyst Rating Update from Morgan Stanley | VRTX Stock News
VRTX: JP Morgan Raises Price Target to $530 | VRTX Stock News
VRTX: JP Morgan Raises Price Target to $530 | VRTX Stock News
Spotlight on Vertex Pharmaceuticals: Analyzing the Surge in Options Activity
Whales with a lot of money to spend have taken a noticeably bullish stance on Vertex Pharmaceuticals . Looking at options history for Vertex Pharmaceuticals (NASDAQ: VRTX) we detected 10 trades. If w...
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Vertex to Announce Third Quarter 2025 Financial Results on November 3rd
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2025 financial results on Monday, November 3, 2025, after the financial markets close. The com...
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years
Vertex Pharmaceuticals (NASDAQ: VRTX) has outperformed the market over the past 20 years by 6.5% on an annualized basis producing an average annual return of 15.61%. Currently, Vertex Pharmaceuticals...
Noteworthy ETF Outflows: VUG, SYK, BX, VRTX
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Growth ETF (Symbol: VUG) where we have detected an approximat...
Insider Sell: Jonathan Biller Sells Shares of Vertex Pharmaceuticals Inc (VRTX)
Insider Sell: Jonathan Biller Sells Shares of Vertex Pharmaceuticals Inc (VRTX)
Vertex Pharmaceuticals (VRTX) Stock Dips While Market Gains: Key Facts
In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $403.3, indicating a -1.36% shift from the previous trading day.
ServiceNow, Vertex Pharmaceuticals And More: CNBC's 'Final Trades'
On CNBC's “ Halftime Report Final Trades ,” on Thursday, Jason Snipe , founder and chief investment officer of Odyssey Capital Advisors, said he likes ServiceNow, Inc. (NYSE: NOW), which is down 14% ...
Vertex Pharmaceuticals (VRTX) Exceeds Market Returns: Some Facts to Consider
The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $408.85, representing a +1.15% change from its previous close.
Vertex Pharmaceuticals (VRTX) Receives Raised Price Target from Citigroup | VRTX Stock News
Vertex Pharmaceuticals (VRTX) Receives Raised Price Target from Citigroup | VRTX Stock News
Final Trades: ServiceNow, Vertex Pharmaceuticals and the IJR
CNBC's “Halftime Report” team discuss their top stocks and final trades.
Final Trades: ServiceNow, Vertex Pharmaceuticals and the IJR
CNBCs Halftime Report team discuss their top stocks and final trades.